Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study
Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Lionel Adès(Centre National de la Recherche Scientifique), F. Scarci(Helsinn (Switzerland)), Agnieszka Wierzbowska(Medical University of Lodz), Gianluca Ballinari(Helsinn (Switzerland)), Maciej Kaźmierczak(Silesian University of Technology), Michael Keng(University of Virginia), Chun Yew Fong(Olivia Newton-John Cancer Wellness & Research Centre)
Cited by 12
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714